Navigation Links
Majority of Surveyed Pharmacy Directors Expect To Cover Pfizer's Tanezumab If It Is Approved for the Treatment of Chronic Pain
Date:12/15/2009

NASHVILLE, Tenn. and GLEN ROCK, N.J., Dec. 15 /PRNewswire/ -- HealthLeaders-InterStudy and Fingertip Formulary find that 70 percent of surveyed pharmacy directors expect to cover Pfizer's tanezumab if it is approved for the treatment of chronic pain. Tanezumab, which is expected to be the first biologic approved for chronic pain and is administered intravenously under medical supervision, will likely be covered as a medical benefit rather than a pharmacy benefit according to surveyed pharmacy directors. According to the new Formulary Forum report entitled Formulary Advantages in Chronic Pain Therapies: How Will Price Impact the Coverage of Expensive Abuse-Deterrent Opioids and Biologics?, nearly half of surveyed pharmacy directors (48%) say they expect to cover tanezumab as both a medical and pharmacy benefit.

Survey findings indicate that as the price of tanezumab drops, more pharmacy directors are willing to cover the drug for patients with back pain. Moreover, pharmacy directors indicate that at lower prices they are willing to cover tanezumab for more back pain patients, regardless of whether the patient is eligible for surgery.

"Our survey finds that as the price of tanezumab decreases more pharmacy directors say they will not only cover the drug, but they will cover it for a larger patient group. However, they still require patients to fail multiple lines of pharmacotherapy before they will reimburse the drug," said Analyst Cindy Fung, Ph.D. "Survey findings also indicate that there's a limit to the number of plans that will cover tanezumab. Even at the lowest price surveyed, 15 percent of surveyed pharmacy directors say they will exclude the drug from their formularies."

The new Formulary Forum report is based on a survey of 50 U.S. pharmacy directors who control formularies at national, regional and state-level managed care organizations, as well as historical formulary data from Fingertip Formulary.

About Fingertip Formulary

Fingertip Formulary (www.FingertipFormulary.com), the leading provider of access to and insight into formulary data in the United States, offers comprehensive formulary data covering commercial, Medicaid, Medicare and PBM plans, among others. Fingertip Formulary is a Decision Resources, Inc. company.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit www.HL-ISY.com.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Both HealthLeaders-InterStudy and Fingertip Formulary are Decision Resources, Inc. companies. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


    For more information, contact:

    Lisa Osgood                               Elizabeth Marshall
    HealthLeaders-InterStudy                  Decision Resources, Inc.
    781-296-2606                              781-296-2563
    losgood@hl-isy.com                        emarshall@dresources.com

SOURCE HealthLeaders-InterStudy


'/>"/>
SOURCE HealthLeaders-InterStudy
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
2. Aspirin Named 8th World Wonder by Majority of Americans
3. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
4. Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections
5. Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
6. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
7. Giant Eagle(R) Pharmacy Receives Award for Operational Excellence
8. Pharmacy Technician Employment Increasing Up to 32% By 2016
9. Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting
10. Amber Pharmacy Earns Accreditation From ACHC
11. Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Health, Inc. (Nasdaq: GHDX ) today reported financial results ... 2015. --> --> Revenue was ... million in the fourth quarter of 2014, an increase of 8 ... with the same period in the prior year. ... the fourth quarter of 2015, an increase of 9 percent compared ...
(Date:2/10/2016)... LEXINGTON, Massachusetts , February 10, 2016 --> ... Japan .  --> Japan .  ... Japan .  With submission, Shire continues to ... --> With submission, Shire continues to ... With submission, Shire continues to strengthen ...
(Date:2/10/2016)... and SAN DIEGO , Feb. ... a global leader in viral gene therapy manufacturing, and ... for congestive heart failure and other chronic diseases, have ... scalable manufacturing process and produce cGMP-grade RT-100 (Ad5.hAC6) Drug ... --> --> This ...
Breaking Medicine Technology:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Ongoing news ... Aging Life Care Association™ (ALCA) to conduct a survey that takes a closer look ... released today illustrates the prevalence and causes of TBI among the aging population, and ...
(Date:2/10/2016)... ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a ... for the fourth quarter and full year ended December 31, 2015 on Monday, February ... and webcast for the investment community following the release at 4:30 PM ET. Investors ...
(Date:2/10/2016)... ... ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves with age, ... Guide to Brain Training" by award-winning author Phyllis Strupp explains how brain ... 16, 2016. A free review copy is available to the media at NetGalley ...
(Date:2/10/2016)... ... 2016 , ... IDEX Health & Science, LLC announces the ... columns combine the strength of traditional stainless steel with the chemical inertness of ... operating at ultra-high pressures of 20,000 psi. The higher operating pressures allow faster ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... The recreational ... cannabis enthusiasts in the state still face a lot of restrictions as to where ... is intended for private, personal use” and that cannabis “may not be consumed openly ...
Breaking Medicine News(10 mins):